Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi

suck pdf from google scholar
PDF vom PMID32532939 :   free

suck abstract from ncbi

Nephropedia Template TP Text

Twit Text FOAVip

Twit Text #

English Wikipedia

  • The rationale for Low-Molecular Weight Heparin (LMWH) use in SARS-CoV-2 infection #MMPMID32532939
  • Di Perri G
  • Infez Med 2020[Jun]; 28 (suppl 1): 52-56 PMID32532939show ga
  • In spite of many ongoing attempts to repurpose existing antivirals, no drugs have emerged yet with the desirable activity against SARS-CoV-2. Hydroxychloroquine, lopinavir/ritonavir, remdesivir, umifenovir, favipiravir, ribavirin and beta-interferon-1 gave rise to variable but still inconsistent proof of clinical efficacy in the treatment of COVID-19. Pathogenetic studies have shown significant differences between commonly defined viral pneumonia and COVID-19 pulmonary disease. In severe forms, immune/inflammatory alterations reminiscent of disease forms like Macrophage Activation Syndrome (MAS) have been described, and therapeutic options other than anti-infective have been proposed and implemented, such as anti-inflammatory and anticoagulative agents. The thrombotic phenomena described in the pulmonary vascular bed of patients with severe COVID-19 suggest the administration of low-molecular weight heparin (LMWH) as standard measure in hospitalized patients with COVID-19.
  • |Adenosine Monophosphate/analogs & derivatives/therapeutic use[MESH]
  • |Alanine/analogs & derivatives/therapeutic use[MESH]
  • |Anticoagulants/administration & dosage/*therapeutic use[MESH]
  • |Antiviral Agents/administration & dosage/therapeutic use[MESH]
  • |Biomarkers[MESH]
  • |COVID-19[MESH]
  • |Coronavirus Infections/blood/*complications/drug therapy/physiopathology[MESH]
  • |Critical Care/*methods[MESH]
  • |Disease Management[MESH]
  • |Double-Blind Method[MESH]
  • |Drug Combinations[MESH]
  • |Drug Therapy, Combination[MESH]
  • |Embolism/epidemiology/prevention & control[MESH]
  • |Endothelium, Vascular/physiopathology[MESH]
  • |Heparin, Low-Molecular-Weight/administration & dosage/*therapeutic use[MESH]
  • |Humans[MESH]
  • |Hydroxychloroquine/therapeutic use[MESH]
  • |Interferon beta-1b/therapeutic use[MESH]
  • |Lopinavir/therapeutic use[MESH]
  • |Macrophage Activation[MESH]
  • |Pandemics[MESH]
  • |Pneumonia, Viral/blood/*complications/drug therapy/physiopathology[MESH]
  • |Pulmonary Fibrosis/etiology/prevention & control[MESH]
  • |Randomized Controlled Trials as Topic[MESH]
  • |Ritonavir/therapeutic use[MESH]
  • |Thromboembolism/epidemiology/prevention & control[MESH]
  • |Thrombophilia/blood/*drug therapy/etiology[MESH]
  • |Thrombosis/epidemiology/prevention & control[MESH]

  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    52 suppl 1.28 2020